Earnings Release • Apr 28, 2015
Earnings Release
Open in ViewerOpens in native device viewer
Philips reports Q1 comparable sales growth of 2% to EUR 5.3 billion and operational results of EUR 327 million
"We are encouraged by the resumption of sales growth in the first quarter of 2015, which was driven by continued strong performance in Consumer Lifestyle and positive comparable sales growth in Healthcare. We saw positive order-intake growth, despite the continued challenging Healthcare market environment. In line with our strategy to capture a larger portion of the HealthTech opportunities across the health continuum, we stepped up our investments in, among others, healthcare informatics, personal health solutions and our quality systems. We have also substantially improved our position in the growing image-guided therapy market through the acquisition of Volcano. Our investments, coupled with negative currency eects, are the main reasons for the low profitability in Healthcare in the first quarter. We also continued to make good progress in ramping up production and shipments from our Cleveland manufacturing facility, and are on track to deliver on our profit improvement plan for our diagnostic imaging business for the year.
We saw continued strong sales growth and profitability improvement in our LED business, while facing a faster decline in the conventional lighting business and underperformance in our Professional Lighting business in North America. We continue to proactively rationalize our conventional lighting operations and are confident in our conventional lighting business' ability to sustain its attractive cash and profitability profile. We are pleased with the terms of the agreement to sell a majority stake in the combined LED components and Automotive lighting business to a consortium led by GO Scale Capital and expect to close this deal in the third quarter of 2015, subject to regulatory approvals.
For 2015, we expect modest comparable sales growth and we continue to be focused on driving operational performance improvements to increase the EBITA margin. Our 2016 target trajectory as announced in January remains unchanged."
"Our Accelerate! program continues to drive improvements across the organization, resulting in enhanced customer centricity and service levels, faster time-to-market for our innovations, strengthened quality and compliance systems, and better cost productivity."
In Healthcare, we were able to reduce the Ingenia MRI installation time by 60% and installation cost by 30%, by redesigning and harmonizing the end-to-end processes across the equipment installation value chain. In Consumer Lifestyle, the deployment of Lean allowed the Male Grooming team to reduce the lead-time for development and launch of a new range of shavers by 30%. The team was able to simplify the end-to-end processes and re-use existing technology platforms. In Lighting, thanks to a faster time-to-market, a new range of basic LED lamps with a price point below USD 5.00 was successfully launched for the North American market within only four months.
We are making good progress in setting up two stand-alone, fit-for-purpose companies. We are also working on defining the optimal infrastructure and right perimeter for each business, including tax and legal structures, real estate footprint and IT systems. We have simplified the operating model and strengthened our leadership team, most recently with Rob Cascella joining us to oversee our cluster of imaging businesses. Rob was previously CEO of Hologic and brings a wealth of healthcare experience to Philips."
The transition of the Lighting business into a separate legal structure will take at least until the end of 2015, in order to be ready for the separation, which is currently intended to be effectuated through an IPO in the first half of 2016. At the same time, alternatives will continue to be carefully reviewed. Further updates will be provided over the course of the year. The company continues to estimate that separation costs will be in the range of EUR 300-400 million in 2015.
Overhead cost savings amounted to EUR 19 million in the first quarter. The Design for Excellence (DfX) program generated EUR 47 million of incremental savings in procurement in the quarter. Our End2End productivity program achieved EUR 37 million in productivity improvements.
As of March 31, 2015, Philips had completed 50% of the EUR 1.5 billion share buy-back program.
Healthcare comparable sales grew 1% year-over-year. Excluding restructuring and acquisition-related charges and other items, EBITA margin was 5.4%, down from 8.8% year-on-year, mainly driven by investments and remediation costs. Currency-comparable order intake showed low-single-digit growth, with positive performance in Europe, North America and other growth geographies partially offset by China.
"We were pleased that order intake and sales returned to growth, despite a challenging healthcare environment. Performance at recently acquired Volcano was on track in the first quarter. Our ability to engage with customers on end-to-end solutions across the health continuum is increasingly proving to be a defining competitive advantage. We closed additional multi-year contracts, including a sevenyear agreement with Providence Health & Services in the US and a multi-year agreement with the Kenyan Ministry of Health. We also signed a multi-year collaboration agreement with Janssen Pharmaceutica to develop a new handheld blood test."
Consumer Lifestyle comparable sales increased by 10%. EBITA margin, excluding restructuring and acquisition-related charges and other items, was 11.4% of sales, compared to 10.6% of sales in Q1 2014. The increase was largely due to a combination of operational leverage and product mix, which was partially offset by negative currency effects.
"Building on our strategy to deliver locally relevant innovations through strong marketing activation and increased share of online sales, our Consumer Lifestyle business continued to deliver great results and market share gains, with a particularly strong performance from our Health & Wellness portfolio.
For example, Philips is uniquely positioned to develop the Oral Health Care market. We continue to introduce exciting innovations, including the Philips Sonicare for Kids Connected toothbrush, the Sonicare AirFloss Ultra and the Adaptive Clean brush head. By making our products connected, there is future potential for data generation and integration into the cloud-based HealthSuite Digital Platform to ultimately provide total health and well-being solutions."
Lighting (excluding the combined businesses of Lumileds and Automotive) comparable sales declined 3% year-on-year. On a nominal basis, sales increased by 9%, mainly due to positive currency effects. LED-lighting sales grew 25%, offset by a decline of 16% in overall conventional lighting sales. LED sales now represent 39% of total Lighting sales, compared to 30% in Q1 2014. EBITA margin, excluding restructuring and acquisition-related charges and other items, amounted to 8.4%, compared to 8.0% in Q1 2014. The increase was mainly driven by improved operational performance of LED and Professional Lighting Solutions, partly offset by the decline in conventional.
"We are pleased with the continued increase in LED margins, while having to manage through a faster-than-expected decline in conventional lighting and unsatisfactory overall performance in China and North America, which we are actively addressing. We are expanding our portfolio of connected lighting products for the home with innovations such as Philips Hue Phoenix, the first luminaire that provides dimmable white light. We also made further inroads with our CityTouch lighting systems, with Los Angeles, for example, adopting an advanced Philips management system that uses mobile and cloud-based technologies to control its street lighting. Philips' CityTouch connected lighting management system is now used in more than 250 cities globally."
Sales increased to EUR 169 million in the first quarter of 2015 from EUR 138 million in the first quarter of 2014, mainly due to higher onetime licensing revenue in IP Royalties. EBITA was a net cost of EUR 89 million, compared to a net cost of EUR 103 million in the first quarter of 2014.
"To further strengthen the digital pathology business within our Healthcare Incubator, we entered into a joint development agreement with Mount Sinai Health System in New York to create a state-of-the-art digital pathology database from hundreds of thousands of tissue samples and to develop innovative algorithms to ultimately enable more personalized patient care.
In the first quarter, we completed the de-risking of the Dutch pension plan initiated in 2014, through a final payment of EUR 171 million. Consequently, we will apply defined-contribution pension accounting for the Dutch plan from the second quarter onwards. We intend to pursue further substantial pension de-risking opportunities in other geographies in the coming quarters and will report on our progress later in the year."
Frans van Houten, CEO, and Ron Wirahadiraksa, CFO, will host a conference call for investors and analysts at 10:00 am CET to discuss the results. A live audio webcast of the conference call will be available on the Philips Investor Relations website.
| Net income in millions of EUR unless otherwise stated | |||
|---|---|---|---|
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Sales | 4,692 | 5,339 |
| EBITA | 253 | 230 |
| as a % of sales | 5.4% | 4.3% |
| EBIT | 172 | 139 |
| as a % of sales | 3.7% | 2.6% |
| Financial income (expenses) | (69) | (67) |
| Income taxes | (28) | (31) |
| Results investments in associates | 21 | 23 |
| Net income from continuing operations | 96 | 64 |
| Discontinued operations | 41 | 36 |
| Net income | 137 | 100 |
| Net income attributable to shareholders per common share (in EUR) - diluted |
0.15 | 0.11 |
Sales by sector in millions of EUR unless otherwise stated
| % change | ||||
|---|---|---|---|---|
| Q1 2014 | Q1 2015 | nomi nal |
compar able |
|
| Healthcare | 1,966 | 2,261 | 15% | 1% |
| Consumer Lifestyle | 1,016 | 1,190 | 17% | 10% |
| Lighting | 1,572 | 1,719 | 9% | (3)% |
| Innovation, Group & Services |
138 | 169 | 22% | 15% |
| Philips Group | 4,692 | 5,339 | 14% | 2% |
Sales per geographic cluster in millions of EUR unless otherwise stated
| % change | ||||
|---|---|---|---|---|
| Q1 2014 | Q1 2015 | nomi nal |
compar able |
|
| Western Europe | 1,281 | 1,334 | 4% | 2% |
| North America | 1,491 | 1,753 | 18% | 0% |
| Other mature geographies |
415 | 443 | 7% | (2)% |
| Total mature geographies |
3,187 | 3,530 | 11% | 0% |
| Growth geographies | 1,505 | 1,809 | 20% | 6% |
| Philips Group | 4,692 | 5,339 | 14% | 2% |
| Q1 2014 | Q1 2015 | ||||
|---|---|---|---|---|---|
| amount | % | amount | % | ||
| Healthcare | 152 | 7.7% | 65 | 2.9% | |
| Consumer Lifestyle | 108 | 10.6% | 135 | 11.3% | |
| Lighting | 96 | 6.1% | 119 | 6.9% | |
| Innovation, Group & Services |
(103) | – | (89) | – | |
| Philips Group | 253 | 5.4% | 230 | 4.3% |
| in millions of EUR unless otherwise stated | |||||
|---|---|---|---|---|---|
| Q1 2014 | Q1 2015 | ||||
| amount | % | amount | % | ||
| Healthcare | 173 | 8.8% | 123 | 5.4% | |
| Consumer Lifestyle | 108 | 10.6% | 136 | 11.4% | |
| Lighting | 126 | 8.0% | 144 | 8.4% | |
| Innovation, Group & Services |
(103) | – | (76) | – | |
| Philips Group | 304 | 6.5% | 327 | 6.1% |
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Healthcare | 109 | 17 |
| Consumer Lifestyle | 96 | 122 |
| Lighting | 73 | 93 |
| Innovation, Group & Services | (106) | (93) |
| Philips Group | 172 | 139 |
| as a % of sales | 3.7% | 2.6% |
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Beginning cash balance | 2,465 | 1,873 |
| Free cash "ow | (431) | (443) |
| Net cash flow from operating activities |
(273) | (256) |
| Net capital expenditures | (158) | (187) |
| Acquisitions and divestments of businesses |
(18) | (1,066) |
| Other cash "ow from investing activities |
– | (17) |
| Treasury shares transactions | (107) | (108) |
| Changes in debt | (181) | 1,190 |
| Other cash "ow items | (18) | 174 |
| Net cash "ow discontinued operations | 17 | 64 |
| Ending balance | 1,727 | 1,667 |
Gross capital expenditures1) in millions of EUR
▪ Operating activities resulted in a cash outow of EUR 256 million, compared to an outow of EUR 273 million in Q1 2014. Lower cash earnings were more than offset by improved working capital.
▪ Gross capital expenditures on property, plant and equipment were EUR 10 million above the level of Q1 2014, with increases in the operating sectors partly offset by lower investments at IG&S.
1) Sales is calculated over the preceding 12 months
2) Inventories as a % of sales excludes inventories and sales related to acquisitions, divestments and discontinued operations
1) Number of employees excludes discontinued operations. Discontinued operations had 8,334 employees in Q1 2015 (Q4 2014: 8,313, Q1 2014: 9,957).
2) Number of employees includes 13,930 third-party workers in Q1 2015 (Q4 2014: 12,867, Q1 2014: 11,861).
| Key data in millions of EUR unless otherwise stated | ||||
|---|---|---|---|---|
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Sales | 1,966 | 2,261 |
| Sales growth | ||
| % nominal | (8)% | 15% |
| % comparable | (2)% | 1% |
| EBITA | 152 | 65 |
| as a % of sales | 7.7% | 2.9% |
| EBIT | 109 | 17 |
| as a % of sales | 5.5% | 0.8% |
| Net operating capital (NOC) | 7,443 | 9,400 |
| Number of employees (FTEs)1) | 36,506 | 38,901 |
1) Number of employees includes 2,626 third-party workers in Q1 2015 (Q1 2014: 2,118).
*Order intake includes equipment and software orders
▪ Restructuring and acquisition-related charges in Q2 2015 are expected to total approximately EUR 30 million.
| Key data in millions of EUR unless otherwise stated | |
|---|---|
| -- | ----------------------------------------------------- |
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Sales | 1,016 | 1,190 |
| Sales growth | ||
| % nominal | 1% | 17% |
| % comparable | 7% | 10% |
| EBITA | 108 | 135 |
| as a % of sales | 10.6% | 11.3% |
| EBIT | 96 | 122 |
| as a % of sales | 9.4% | 10.3% |
| Net operating capital (NOC) | 1,321 | 1,598 |
| Number of employees (FTEs)1) | 17,103 | 17,048 |
1) Number of employees includes 4,118 third-party workers in Q1 2015 (Q1 2014: 4,077).
▪ Restructuring and acquisition-related charges in Q2 2015 are expected to be less than EUR 5 million.
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Sales | 1,572 | 1,719 |
| Sales growth | ||
| % nominal | (8)% | 9% |
| % comparable | (3)% | (3)% |
| EBITA | 96 | 119 |
| as a % of sales | 6.1% | 6.9% |
| EBIT | 73 | 93 |
| as a % of sales | 4.6% | 5.4% |
| Net operating capital (NOC) | 4,484 | 3,927 |
| Number of employees (FTEs)1) | 37,897 | 38,026 |
1) Number of employees includes 5,710 third-party workers in Q1 2015 (Q1 2014: 4,603)
▪ Restructuring and acquisition-related charges in Q2 2015 are expected to total approximately EUR 30 million, mainly driven by industrial footprint rationalization.
The combined businesses of Lumileds and Automotive are reported as discontinued operations in the Consolidated statements of income and cash ows. As a result, Lumileds and Automotive sales and EBITA are no longer included in the Lighting and Group results of continuing operations. The applicable assets and liabilities of the combined businesses are reported under Assets and Liabilities classified as held for sale in the Condensed consolidated balance sheets.
As announced on March 31, 2015, Philips has signed an agreement with a consortium led by GO Scale Capital, through which they will acquire an 80.1% interest in Philips' combined LED components and Automotive lighting business, with Philips retaining the remaining 19.9%* interest. The transaction is expected to be completed in the third quarter of 2015, subject to closing conditions, including customary regulatory approvals.
In Q1 2015, the net income of discontinued operations attributable to the combined businesses of Lumileds and Automotive decreased from EUR 43 million in Q1 2014 to EUR 37 million. EBITA in Q1 2015 included disentanglement costs of EUR 19 million, compared to nil in Q1 2014.
Overhead and other indirect costs of Philips that were previously allocated to Lumileds and Automotive and were not affected by the transfer to Discontinued operations have been allocated to Lighting and IG&S (Former net costs allocated to Lighting and IG&S).
*including a 34% interest in Lumileds' US operations
Combined businesses of Lumileds and Automotive results in millions of EUR unless otherwise stated
| Q1 2014 | Q1 2015 | |
|---|---|---|
| EBITA as previously reported in Lighting | 41 | 33 |
| Adjustment of amortization and depreciation following assets held for sale reclassification |
42 | |
| Disentanglement costs | – | (19) |
| Former net costs allocated to Lighting | – | (1) |
| Former net costs allocated to IG&S | 19 | 23 |
| Amortization of other intangibles added back |
(6) | – |
| EBIT of discontinued operations | 54 | 78 |
| Income taxes | (11) | (41) |
| Net income of discontinued operations | 43 | 37 |
| Number of employees (FTEs) | 7,762 | 8,334 |
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Sales | 138 | 169 |
| Sales growth | ||
| % nominal | 0% | 22% |
| % comparable | (7)% | 15% |
| EBITA of: | ||
| Group Innovation | (47) | (53) |
| IP Royalties | 69 | 87 |
| Group and Regional Costs | (35) | (69) |
| Accelerate! investments | (29) | (28) |
| Pensions | (2) | (3) |
| Service Units and Other | (59) | (23) |
| EBITA | (103) | (89) |
| EBIT | (106) | (93) |
| Net operating capital (NOC) | (2,867) | (3,948) |
| Number of employees (FTEs)1) | 12,805 | 13,661 |
1) Number of employees includes 1,476 third-party workers in Q1 2015 (Q1 2014: 1,063)
▪ Restructuring and separation charges in Q2 2015 are expected to total approximately EUR 65 million.
This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
These factors include but are not limited to domestic and global economic and business conditions, developments within the euro zone, the successful implementation of Philips' strategy and the ability to realize the benefits of this strategy, the ability to develop and market new products, changes in legislation, legal claims, changes in exchange and interest rates, changes in tax rates, pension costs and actuarial assumptions, raw materials and employee costs, the ability to identify and complete successful acquisitions, including Volcano, and to integrate those acquisitions into the business, the ability to successfully exit certain businesses or restructure the operations, the rate of technological changes, political, economic and other developments in countries where Philips operates, industry consolidation and competition. As a result, Philips' actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see the Risk management chapter included in the Annual Report 2014.
Statements regarding market share, including those regarding Philips' competitive position, contained in this document are based on outside sources such as research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, those statements may also be based on estimates and projections prepared by outside sources or management. Rankings are based on sales unless otherwise stated.
In presenting and discussing the Philips Group financial position, operating results and cash ows, management uses certain non-GAAP financial measures. These non-GAAP financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used in conjunction with the most directly comparable IFRS measures. Non-GAAP financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-GAAP measures to the most directly comparable IFRS measures is contained in this document. Further information on non-GAAP measures can be found in the Annual Report 2014.
In presenting the Philips Group financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2014. Independent valuations may have been obtained to support management's determination of fair values.
All amounts are in millions of euros unless otherwise stated. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2014, unless otherwise stated.
The presentation of certain prior-year information has been reclassified to conform to the current-year presentation.
In 2014, we announced plans to establish two standalone companies focused on the HealthTech and Lighting Solutions opportunities. The proposed separation of the Lighting business impacts all businesses and markets as well as all supporting functions and all assets and liabilities of the Group. Philips expects the separation will take approximately 12-18 months. We expect to continue reporting in the existing structure until the changes in the way we allocate resources and analyze performance in the new structure have been completed.
| Consolidated statements of income in millions of EUR unless otherwise stated | |
|---|---|
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Sales | 4,692 | 5,339 |
| Cost of sales | (2,792) | (3,223) |
| Gross margin | 1,900 | 2,116 |
| Selling expenses | (1,166) | (1,341) |
| General and administrative expenses | (167) | (214) |
| Research and development expenses | (396) | (436) |
| Impairment of goodwill | (3) | – |
| Other business income | 10 | 22 |
| Other business expenses | (6) | (8) |
| Income from operations | 172 | 139 |
| Financial income | 16 | 31 |
| Financial expenses | (85) | (98) |
| Income before taxes | 103 | 72 |
| Income tax expense | (28) | (31) |
| Income after taxes | 75 | 41 |
| Results relating to investments in associates | 21 | 23 |
| Net income from continuing operations | 96 | 64 |
| Discontinued operations - net of income tax | 41 | 36 |
| Net income | 137 | 100 |
| Attribution of net income for the period | ||
| Net income attributable to Koninklijke Philips N.V. shareholders | 138 | 99 |
| Net income (loss) attributable to non-controlling interests | (1) | 1 |
| Earnings per common share attributable to shareholders | ||
| Weighted average number of common shares outstanding (after deduction of treasury shares) during the period (in thousands): |
||
| - basic | 913,990 | 912,086 |
| - diluted | 925,674 | 918,215 |
| Net income attributable to shareholders per common share in EUR: | ||
| - basic | 0.15 | 0.11 |
| - diluted | 0.15 | 0.11 |
Consolidated balance sheets in millions of EUR
| March 30, 2014 | December 31, 2014 | March 31, 2015 | |
|---|---|---|---|
| Non-current assets: | |||
| Property, plant and equipment | 2,709 | 2,095 | 2,344 |
| Goodwill | 6,502 | 7,158 | 8,596 |
| Intangible assets excluding goodwill | 3,171 | 3,368 | 3,985 |
| Non-current receivables | 148 | 177 | 195 |
| Investments in associates | 182 | 157 | 173 |
| Other non-current financial assets | 487 | 462 | 512 |
| Non-current derivative financial assets | 36 | 15 | 63 |
| Deferred tax assets | 1,789 | 2,460 | 2,677 |
| Other non-current assets | 57 | 69 | 89 |
| Total non-current assets | 15,081 | 15,961 | 18,634 |
| Current assets: | |||
| Inventories | 3,449 | 3,314 | 3,916 |
| Other current financial assets | 11 | 125 | 125 |
| Other current assets | 414 | 411 | 537 |
| Current derivative financial assets | 71 | 192 | 288 |
| Income tax receivable | 70 | 140 | 118 |
| Receivables | 4,612 | 4,723 | 4,917 |
| Assets classified as held for sale | 539 | 1,613 | 1,591 |
| Cash and cash equivalents | 1,727 | 1,873 | 1,667 |
| Total current assets | 10,893 | 12,391 | 13,159 |
| Total assets | 25,974 | 28,352 | 31,793 |
| Equity | |||
| Shareholders' equity | 11,015 | 10,867 | 11,382 |
| Non-controlling interests | 10 | 101 | 114 |
| Group equity | 11,025 | 10,968 | 11,496 |
| Non-current liabilities: | |||
| Long-term debt | 3,311 | 3,712 | 4,118 |
| Non-current derivative financial liabilities | 284 | 551 | 798 |
| Long-term provisions | 1,876 | 2,500 | 2,575 |
| Deferred tax liabilities | 55 | 107 | 106 |
| Other non-current liabilities | 1,503 | 1,838 | 2,066 |
| Total non-current liabilities | 7,029 | 8,708 | 9,663 |
| Current liabilities: | |||
| Short-term debt | 406 | 392 | 1,667 |
| Current derivative financial liabilities | 75 | 306 | 590 |
| Income tax payable | 121 | 102 | 154 |
| Accounts and notes payable | 2,714 | 2,499 | 2,913 |
| Accrued liabilities | 2,518 | 2,692 | 2,778 |
| Short-term provisions | 644 | 945 | 862 |
| Liabilities directly associated with assets held for sale | 319 | 349 | 335 |
| Other current liabilities | 1,123 | 1,391 | 1,335 |
| Total current liabilities | 7,920 | 8,676 | 10,634 |
| Total liabilities and group equity | 25,974 | 28,352 | 31,793 |
Consolidated statements of cash flows in millions of EUR
| Q1 2014 | Q1 2015 | |
|---|---|---|
| Cash flows from operating activities | ||
| Net income | 137 | 100 |
| Result of discontinued operations - net of income tax | (41) | (36) |
| Adjustments to reconcile net income to net cash provided by (used for) operating activities: | ||
| Depreciation, amortization, and impairments of fixed assets | 260 | 283 |
| Impairment of goodwill and other non-current financial assets | 13 | – |
| Net gain on sale of assets | (6) | (34) |
| Interest income | (8) | (14) |
| Interest expense on debt, borrowings and other liabilities | 51 | 66 |
| Income tax expense | 28 | 31 |
| Results from investments in associates | (21) | (2) |
| (Increase) decrease in working capital: | (131) | (18) |
| Decrease in receivables and other current assets | 7 | 82 |
| Increase in inventories | (225) | (243) |
| Increase in accounts payable, accrued and other liabilities | 87 | 143 |
| Decrease (increase) in non-current receivables, other assets and other liabilities | (380) | 42 |
| Decrease in provisions | (16) | (162) |
| Other items | 25 | (365) |
| Interest paid | (89) | (101) |
| Interest received | 8 | 14 |
| Income taxes paid | (103) | (60) |
| Net cash used for operating activities | (273) | (256) |
| Cash flows from investing activities | ||
| Net capital expenditures | (158) | (187) |
| Purchase of intangible assets | (11) | (28) |
| Expenditures on development assets | (68) | (72) |
| Capital expenditures on property, plant and equipment | (82) | (92) |
| Proceeds from sale of property, plant and equipment | 3 | 5 |
| Net proceeds from (used for) derivatives and current financial assets | 2 | (37) |
| Purchase of other non-current financial assets | (4) | – |
| Proceeds from other non-current financial assets | 2 | 20 |
| Purchase of businesses, net of cash acquired | (17) | (1,103) |
| Net proceeds from (used for) sale of interest in businesses | (1) | 37 |
| Net cash used for investing activities | (176) | (1,270) |
| Cash flows from financing activities | ||
| Proceeds from issuance of short-term debt | 78 | 1,192 |
| Principal payments on long-term debt | (273) | (20) |
| Proceeds from issuance of long-term debt | 14 | 18 |
| Treasury shares transactions (net) | (107) | (108) |
| Net cash (used for) provided by financing activities | (288) | 1,082 |
| Net cash used for continuing operations | (737) | (444) |
| Cash flows from discontinued operations | ||
| Net cash provided by operating activities | 17 | 64 |
| Net cash provided by discontinued operations | 17 | 64 |
| Net cash used for continuing and discontinued operations | (720) | (380) |
| Effect of change in exchange rates on cash and cash equivalents | (18) | 174 |
| Cash and cash equivalents at the beginning of the period | 2,465 | 1,873 |
| Cash and cash equivalents at the end of the period | 1,727 | 1,667 |
For a number of reasons, principally the effects of translation differences, certain items in the statements of cash flows do not correspond to the differences between the balance sheet amounts for the respective items.
Consolidated statement of changes in equity in millions of EUR
| capital in excess of par value common shares |
revaluation reserve retained earnings |
available- for-sale financial assets currency translation differences treasury shares at cost cash flow hedges |
total shareholders' equity non-controlling interests Group equity |
||
|---|---|---|---|---|---|
| Balance as of December 31, 2014 |
187 2,181 8,790 |
13 229 |
27 (13) (547) 10,867 |
101 10,968 |
|
| Total comprehensive income |
(34) | (2) 704 |
1 (45) 624 |
1 625 |
|
| Movement non-controlling interest |
12 12 |
||||
| Purchase of treasury shares |
(22) | (145) (167) |
(167) | ||
| Re-issuance of treasury shares |
(5) (21) |
61 35 |
35 | ||
| Share-based compensation plans |
22 | 22 | 22 | ||
| Income tax share-based compensation plans |
1 | 1 | 1 | ||
| Total other equity movements |
18 (43) |
(84) (109) |
12 (97) |
||
| Balance as of March 31, 2015 |
187 2,199 8,713 |
11 933 |
28 (58) (631) 11,382 |
114 11,496 |
Specification of pension costs in millions of EUR
| Q1 2014 | Q1 2015 | |||||
|---|---|---|---|---|---|---|
| Netherlands | other | total | Netherlands | other | total | |
| Defined-benefit plans | ||||||
| Pensions | ||||||
| Current service cost | 45 | 18 | 63 | 60 | 21 | 81 |
| Interest expense | – | 14 | 14 | – | 13 | 13 |
| Interest income | (4) | – | (4) | (1) | – | (1) |
| Total | 41 | 32 | 73 | 59 | 34 | 93 |
| of which discontinued operations | – | 1 | 1 | – | 1 | 1 |
| Retiree Medical | ||||||
| Current service cost | – | – | – | – | – | – |
| Interest expense | – | 3 | 3 | – | 3 | 3 |
| Total | – | 3 | 3 | – | 3 | 3 |
| Defined-contribution plans | ||||||
| Cost | 2 | 37 | 39 | – | 41 | 41 |
| of which discontinued operations | – | 1 | 1 | – | 1 | 1 |
| Pension cash flows in millions of EUR | ||||||||
|---|---|---|---|---|---|---|---|---|
| Q1 2014 | Q1 2015 | |||||||
| Contributions and benefits paid by the Company | (478) | (309) |
| Q1 2014 | Q1 2015 | ||||||
|---|---|---|---|---|---|---|---|
| sales | income from operations | sales | income from operations | ||||
| as a % of sales | as a % of sales | ||||||
| Healthcare | 1,966 | 109 | 5.5% | 2,261 | 17 | 0.8% | |
| Consumer Lifestyle | 1,016 | 96 | 9.4% | 1,190 | 122 | 10.3% | |
| Lighting | 1,572 | 73 | 4.6% | 1,719 | 93 | 5.4% | |
| Innovation, Group & Services | 138 | (106) | – | 169 | (93) | – | |
| Philips Group | 4,692 | 172 | 3.7% | 5,339 | 139 | 2.6% |
| sales | total assets | total liabilities excluding debt | ||||
|---|---|---|---|---|---|---|
| January to March | March 30, | March 31, | March 30, | March 31, | ||
| 2014 | 2015 | 2014 | 2015 | 2014 | 2015 | |
| Healthcare | 1,966 | 2,261 | 10,512 | 13,675 | 2,983 | 4,220 |
| Consumer Lifestyle | 1,016 | 1,190 | 2,830 | 3,250 | 1,509 | 1,652 |
| Lighting | 1,572 | 1,719 | 6,719 | 6,303 | 2,215 | 2,354 |
| Innovation, Group & Services | 138 | 169 | 5,374 | 6,974 | 4,206 | 5,951 |
| 25,435 | 30,202 | 10,913 | 14,177 | |||
| Assets and liabilities classified as held for sale |
539 | 1,591 | 319 | 335 | ||
| Philips Group | 4,692 | 5,339 | 25,974 | 31,793 | 11,232 | 14,512 |
| sales | tangible and intangible assets1) | ||||
|---|---|---|---|---|---|
| January to March | March 30, | March 31, | |||
| 2014 | 2015 | 2014 | 2015 | ||
| Netherlands | 136 | 142 | 895 | 950 | |
| United States | 1,374 | 1,627 | 7,305 | 9,693 | |
| China | 541 | 615 | 1,043 | 1,255 | |
| Germany | 298 | 317 | 285 | 147 | |
| Japan | 254 | 247 | 410 | 425 | |
| France | 192 | 186 | 77 | 50 | |
| India | 139 | 171 | 125 | 146 | |
| Other countries | 1,758 | 2,034 | 2,242 | 2,259 | |
| Philips Group | 4,692 | 5,339 | 12,382 | 14,925 |
1) Includes property, plant and equipment, goodwill, and intangible assets excluding goodwill
Certain non-GAAP financial measures are presented when discussing the Philips Group's performance. In the following tables, reconciliations to the most directly comparable IFRS measures are presented.
| Q1 2015 | |||||||
|---|---|---|---|---|---|---|---|
| comparable growth | currency eƒects | consolidation changes | nominal growth | ||||
| 2015 versus 2014 | |||||||
| Healthcare | 1.4 | 11.4 | 2.2 | 15.0 | |||
| Consumer Lifestyle | 9.8 | 7.3 | 0.0 | 17.1 | |||
| Lighting | (2.9) | 8.8 | 3.5 | 9.4 | |||
| IG&S | 15.2 | 3.8 | 3.5 | 22.5 | |||
| Philips Group | 2.1 | 9.5 | 2.2 | 13.8 |
EBITA excluding restructuring and acquisition-related charges and other items to Income from operations (or EBIT) in millions of EUR
| 2015 | Philips Group | Healthcare | Consumer Lifestyle | Lighting | Innovation, Group & Services |
|---|---|---|---|---|---|
| EBITA excluding restructuring and acquisition related charges and other items |
327 | 123 | 136 | 144 | (76) |
| Other items | (39) | (28) | (11) | ||
| Restructuring and acquisition-related charges | (58) | (30) | (1) | (25) | (2) |
| EBITA (or Adjusted income from operations) | 230 | 65 | 135 | 119 | (89) |
| Amortization of intangibles1) | (91) | (48) | (13) | (26) | (4) |
| Impairment of goodwill | |||||
| Income from operations (or EBIT) | 139 | 17 | 122 | 93 | (93) |
| Income from operations (or EBIT) | 172 | 109 | 96 | 73 | (106) |
|---|---|---|---|---|---|
| Impairment of goodwill | (3) | (1) | (2) | ||
| Amortization of intangibles1) | (78) | (42) | (12) | (21) | (3) |
| EBITA (or adjusted income from operations) | 253 | 152 | 108 | 96 | (103) |
| Restructuring and acquisition-related charges | (51) | (21) | 0 | (30) | 0 |
| related charges and other items | 304 | 173 | 108 | 126 | (103) |
1) Excluding amortization of software and product development
| Q1 2014 | Q1 2015 |
|---|---|
| (273) | (256) |
| (176) | (1,270) |
| (449) | (1,526) |
| (273) | (256) |
| (158) | (187) |
| (11) | (28) |
| (68) | (72) |
| (82) | (92) |
| 3 | 5 |
| (431) | (443) |
Net operating capital to total assets in millions of EUR
| Philips Group | Healthcare | Consumer Lifestyle |
Lighting | IG&S | |
|---|---|---|---|---|---|
| March 31, 2015 | |||||
| Net operating capital (NOC) | 10,977 | 9,400 | 1,598 | 3,927 | (3,948) |
| Exclude liabilities comprised in NOC: | |||||
| - payables/liabilities | 10,634 | 3,218 | 1,359 | 1,710 | 4,347 |
| - intercompany accounts | – | 155 | 74 | 152 | (381) |
| - provisions | 3,437 | 847 | 219 | 492 | 1,879 |
| Include assets not comprised in NOC: | |||||
| - investments in associates | 173 | 55 | – | 22 | 96 |
| - other current financial assets | 125 | 125 | |||
| - other non-current financial assets | 512 | 512 | |||
| - deferred tax assets | 2,677 | 2,677 | |||
| - cash and cash equivalents | 1,667 | 1,667 | |||
| Total assets excluding assets classified as held for sale | 30,202 | 13,675 | 3,250 | 6,303 | 6,974 |
| Assets classified as held for sale | 1,591 | ||||
| Total assets | 31,793 | ||||
| March 30, 2014 | |||||
| Net operating capital (NOC) | 10,381 | 7,443 | 1,321 | 4,484 | (2,867) |
| Exclude liabilities comprised in NOC: | |||||
| - payables/liabilities | 8,338 | 2,551 | 1,251 | 1,671 | 2,865 |
| - intercompany accounts | – | 137 | 72 | 101 | (310) |
| - provisions | 2,520 | 295 | 186 | 443 | 1,596 |
| Include assets not comprised in NOC: | |||||
| - investments in associates | 182 | 86 | – | 20 | 76 |
| - other current financial assets | 11 | 11 | |||
| - other non-current financial assets | 487 | 487 | |||
| - deferred tax assets | 1,789 | 1,789 | |||
| - cash and cash equivalents | 1,727 | 1,727 | |||
| Total assets excluding assets classified as held for sale | 25,435 | 10,512 | 2,830 | 6,719 | 5,374 |
| Assets classified as held for sale | 539 | ||||
| Total assets | 25,974 |
Composition of net debt to group equity in millions of EUR unless otherwise stated
| March 30, 2014 | March 31, 2015 | |
|---|---|---|
| Long-term debt | 3,311 | 4,118 |
| Short-term debt | 406 | 1,667 |
| Total debt | 3,717 | 5,785 |
| Cash and cash equivalents | 1,727 | 1,667 |
| Net debt (cash) (total debt less cash and cash equivalents) | 1,990 | 4,118 |
| Shareholders' equity | 11,015 | 11,382 |
| Non-controlling interests | 10 | 114 |
| Group equity | 11,025 | 11,496 |
| Net debt and group equity | 13,015 | 15,614 |
| Net debt divided by net debt and group equity (in %) | 15% | 26% |
| Group equity divided by net debt and group equity (in %) | 85% | 74% |
| 2014 | 2015 | |||||||
|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| Sales | 4,692 | 4,969 | 5,194 | 6,536 | 5,339 | |||
| comparable sales growth % | (1)% | (1)% | 0% | (2)% | 2% | |||
| Gross margin | 1,900 | 2,075 | 1,702 | 2,529 | 2,116 | |||
| as a % of sales | 40.5% | 41.8% | 32.8% | 38.7% | 39.6% | |||
| Selling expenses | (1,166) | (1,214) | (1,245) | (1,499) | (1,341) | |||
| as a % of sales | (24.9)% | (24.4)% | (24.0)% | (22.9)% | (25.1)% | |||
| G&A expenses | (167) | (176) | (191) | (213) | (214) | |||
| as a % of sales | (3.6)% | (3.5)% | (3.7)% | (3.3)% | (4.0)% | |||
| R&D expenses | (396) | (400) | (372) | (467) | (436) | |||
| as a % of sales | (8.4)% | (8.0)% | (7.2)% | (7.1)% | (8.2)% | |||
| EBIT | 172 | 291 | (139) | 162 | 139 | |||
| as a % of sales | 3.7% | 5.9% | (2.7)% | 2.5% | 2.6% | |||
| EBITA | 253 | 368 | (62) | 262 | 230 | |||
| as a % of sales | 5.4% | 7.4% | (1.2)% | 4.0% | 4.3% | |||
| Net income (loss) | 137 | 243 | (103) | 134 | 100 | |||
| Net income (loss) attributable to shareholders |
138 | 242 | (104) | 139 | 99 | |||
| Net income (loss) - shareholders per common share in EUR - diluted |
0.15 | 0.26 | (0.11) | 0.15 | 0.11 |
| 2014 | 2015 | |||||||
|---|---|---|---|---|---|---|---|---|
| January March |
January June |
January September |
January December |
January March |
January June |
January September |
January December |
|
| Sales | 4,692 | 9,661 | 14,855 | 21,391 | 5,339 | |||
| comparable sales growth % | (1)% | (1)% | (1)% | (1)% | 2% | |||
| Gross margin | 1,900 | 3,975 | 5,677 | 8,206 | 2,116 | |||
| as a % of sales | 40.5% | 41.1% | 38.2% | 38.4% | 39.6% | |||
| Selling expenses | (1,166) | (2,380) | (3,625) | (5,124) | (1,341) | |||
| as a % of sales | (24.9)% | (24.6)% | (24.4)% | (24.0)% | (25.1)% | |||
| G&A expenses | (167) | (343) | (534) | (747) | (214) | |||
| as a % of sales | (3.6)% | (3.6)% | (3.6)% | (3.5)% | (4.0)% | |||
| R&D expenses | (396) | (796) | (1,168) | (1,635) | (436) | |||
| as a % sales | (8.4)% | (8.2)% | (7.9)% | (7.6)% | (8.2)% | |||
| EBIT | 172 | 463 | 324 | 486 | 139 | |||
| as a % of sales | 3.7% | 4.8% | 2.2% | 2.3% | 2.6% | |||
| EBITA | 253 | 621 | 559 | 821 | 230 | |||
| as a % of sales | 5.4% | 6.4% | 3.8% | 3.8% | 4.3% | |||
| Net income | 137 | 380 | 277 | 411 | 100 | |||
| Net income attributable to shareholders | 138 | 380 | 276 | 415 | 99 | |||
| Net income - shareholders per common share in euros - diluted |
0.15 | 0.41 | 0.30 | 0.45 | 0.11 | |||
| Net income from continuing operations as a % of shareholders' equity |
4.0% | 5.7% | 2.0% | 2.0% | 2.4% | |||
| Number of common shares outstanding (after deduction of treasury shares) at the end of period (in thousands) |
913,485 | 923,933 | 919,973 | 914,389 | 910,616 | |||
| Shareholders' equity common share in EUR |
12.06 | 11.63 | 11.86 | 11.88 | 12.50 | |||
| Inventories as a % of sales#) | 14.8% | 15.9% | 17.1% | 15.3% | 17.3% | |||
| Net debt : group equity ratio | 15:85 | 18:82 | 19:81 | 17:83 | 26:74 | |||
| Net operating capital | 10,381 | 10,500 | 10,841 | 8,838 | 10,977 | |||
| Total employees | 114,268 | 112,834 | 115,261 | 113,678 | 115,970 | |||
| of which discontinued operations | 9,957 | 8,256 | 8,489 | 8,313 | 8,334 |
1) Sales is calculated over the preceding 12 months
2) Inventories as a % of sales excludes inventories and sales related to acquisitions, divestments and discontinued operations
http://www.philips.com/investorrelations © 2015 Koninklijke Philips N.V. All rights reserved.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.